The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

Cilta-cel enables sustained MRD negativity in patients with previously treated MM, according to results from the CARTITUDE-4 trial.

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

Perioperative durvalumab improved upon neoadjuvant chemotherapy in patients with cisplatin-eligible MIBC in the NIAGARA trial.

Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with HER2-expressing MIBC.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Adjuvant nivolumab after radical surgery can improve DFS and OS in patients with MIBC, results from the CheckMate 274 trial suggest.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

New research suggests that, from 2011 to 2023, there was an increase in early adult mortality in the United States.

Provider prioritization of relationship-building alongside explanations could foster trust and facilitate open information exchange, supporting informed decisions,” researchers wrote.

Legal experts say the Trump administration’s executive actions to curb government spending could set the stage for major challenges to Congress’ authority to tax and spend.